Alnylam Named #1 Biopharma Employer by Science Magazine
October 24 2019 - 2:11PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that Science magazine has
named the company the world’s number one employer in its annual
survey of the biotech and pharmaceutical industry.
“We are deeply honored to be named the top employer by Science
in the very first year we were included in the survey, as we
continue to build a top-tier, independent biopharmaceutical company
founded on RNAi,” said John Maraganore, Ph.D., Chief Executive
Officer, Alnylam Pharmaceuticals. “This recognition is a testament
to the efforts of our more than 1,200 employees around the world
who work tirelessly every day to advance RNAi therapeutics as a new
class of innovative medicines to patients in need and embodies the
bold scientific endeavor and pioneering spirit that spurred our
founding just over 17 years ago.”
Results were based on 7,658 surveys of people in the industry
who rated companies on attributes such as corporate image,
leadership and direction, work culture/environment, and academic
and intellectual challenge. According to Science, the 2019 global
survey results were based on responses from North America (72
percent), Europe (19 percent) and the Asia/Pacific Rim (7
percent).
“Science has long recognized innovative leaders within our
industry, and we are thrilled to be ranked at the top of this
esteemed list,” said Akshay Vaishnaw, M.D., Ph.D., President,
Research & Development, Alnylam Pharmaceuticals. “It’s quite
gratifying to have our science and culture recognized as we work
hard to discover and develop the next wave of RNAi therapeutics for
patients with serious diseases.”
For the complete feature and company rankings, please visit:
https://www.sciencemag.org/features/2019/10/top-employers-breakthroughs-impact-purpose.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, hepatic infectious, and central
nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically
validated approach for the treatment of a wide range of severe and
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform. Alnylam’s first commercial RNAi
therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU,
Canada, Japan, and Switzerland. Alnylam has a deep pipeline of
investigational medicines, including five product candidates that
are in late-stage development. Looking forward, Alnylam will
continue to execute on its "Alnylam 2020" strategy of building a
multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines to address the needs
of patients who have limited or inadequate treatment options.
Alnylam employs over 1,200 people worldwide and is headquartered in
Cambridge, MA. For more information about our people, science and
pipeline, please visit www.alnylam.com and engage with us on
Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191024005874/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024